How do GLP-1 and GIP receptor agonists reduce overeating beyond simple appetite suppression?

GLP-1 (and dual GLP-1/GIP) receptor agonists tend to reduce overeating through a few overlapping effects that go beyond “you’re less hungry.”

They act on receptors in the brain that regulate appetite, which can dial down cravings and the drive to keep eating for reward or impulse, so it’s often easier to stop at “enough.” At the same time, they slow gastric emptying, meaning food leaves your stomach more slowly, so you feel full longer and smaller meals feel more satisfying. They also support healthier insulin responses and more stable blood sugar, including lowering excess sugar production from the liver, which can reduce the spikes and crashes that often lead to feeling ravenous, snacky, or stuck in a craving loop.

For dual GLP-1/GIP medications like tirzepatide (Zepbound®), the main point is that both receptors are activated, and at Alloy we describe this as potentially leading to enhanced weight loss. The full “why” of that enhanced effect is still an active area of research, but clinically it often shows up as a stronger combined appetite and metabolic effect than GLP-1 alone.

If you want a deeper walkthrough, our article lays it out clearly here: How GLP-1s Support Weight Loss & Metabolic Health and you can also read about our Weight Care program and the GLP-1 options we offer here: Weight Care Program

This answer was created using the following resources: